Classical Hodgkin Lymphoma: ABVD vs BEACOPP Explained

Research-informed explainer — last updated April 12, 2026

Classical Hodgkin lymphoma is one of the most curable cancers we know of, and both ABVD and BEACOPP can get patients there — but they do so with very different risk profiles. BEACOPP produces higher rates of disease control in advanced-stage patients, while ABVD carries substantially less toxicity and is still curative for many. Which regimen is right for you depends on your stage, your age, your fertility plans, and whether your tumor responds early.

This explainer draws on research from three hematologists and lymphoma specialists in the Convene directory at Dana-Farber Cancer Institute and Brigham and Women's Hospital. Eric Jacobsen serves as Clinical Director of the Adult Lymphoma Program at Dana-Farber and published the landmark ECHELON-2 trial of brentuximab vedotin in CD30-positive lymphoma, including Hodgkin-related diseases. Daniel DeAngelo, Chief of the Division of Leukemia, published foundational research on targeted therapy for hematologic malignancies, including mechanisms relevant to understanding why some patients relapse after conventional chemotherapy. Steven Treon, who directs the Bing Center for Waldenström's Research at Dana-Farber, contributed work on the molecular landscape of B-cell lymphoid malignancies and mutation-driven treatment selection.

What's the difference?

ABVD stands for doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine. It has been the standard front-line regimen for classical Hodgkin lymphoma in the United States and much of the world since the 1970s. ABVD is given in cycles, typically six to eight for advanced-stage disease, over four to six months.

BEACOPP stands for bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine (Oncovin), procarbazine, and prednisone. It was developed by the German Hodgkin Study Group as a more intensive regimen intended for patients with advanced or high-risk disease. Escalated BEACOPP uses higher doses of etoposide, doxorubicin, and cyclophosphamide than the baseline version.

Both regimens contain bleomycin, doxorubicin, and vinca alkaloids, but BEACOPP adds alkylating agents (cyclophosphamide and procarbazine) and the topoisomerase inhibitor etoposide. That expanded drug panel is why BEACOPP hits harder — and why it causes more toxicity.

At a glance

What the trials showed

The German Hodgkin Study Group's HD9 trial was the first major randomized comparison to demonstrate that escalated BEACOPP outperformed COPP-ABVD in terms of freedom from treatment failure in advanced-stage Hodgkin lymphoma. Five-year freedom from treatment failure was approximately 69% for the COPP-ABVD group, 76% for standard BEACOPP, and 87% for escalated BEACOPP — a clear dose-intensity advantage.

Subsequent trials attempted to determine whether the efficacy advantage of BEACOPP justified its toxicity. The EORTC 20012 intergroup study compared 8 cycles of ABVD against 4 cycles of escalated BEACOPP plus 4 cycles of baseline BEACOPP in high-risk stage III-IV patients. Results confirmed the pattern: escalated regimens produced higher early remission rates but also higher rates of secondary malignancies, particularly therapy-related acute myeloid leukemia and myelodysplastic syndrome.

The trade-off crystallized in long-term follow-up. The rate of secondary hematologic malignancies after BEACOPP — largely driven by etoposide and the alkylating agents — is meaningfully higher than after ABVD. Since Hodgkin lymphoma has high cure rates with either regimen, the question for many patients becomes: which cancer-related risk matters more — the risk of relapse (where BEACOPP has an edge) or the risk of a treatment-caused secondary malignancy (where ABVD is safer)?

Why CHIP data matters here

Research from Eric Jacobsen's group at Dana-Farber, published in the Journal of Clinical Oncology, examined what happens when lymphoma patients develop clonal hematopoiesis of indeterminate potential (CHIP) — pre-existing mutations in stem cells — and then go on to receive intensive chemotherapy and autologous stem cell transplant [3]. Among 401 patients who underwent autologous transplant, those with CHIP at the time of transplant had a 14% cumulative incidence of therapy-related myeloid neoplasm by 10 years, versus 4% without CHIP. Overall survival was 30% at 10 years for the CHIP group versus 61% without.

This matters for the ABVD vs BEACOPP decision because BEACOPP's alkylating agents and etoposide are precisely the classes of drugs associated with therapy-related myeloid neoplasm [3]. Patients who receive BEACOPP and later require autologous transplant for relapse carry compounded risk. The DNA-damaging agents in BEACOPP may also expand pre-existing CHIP clones, increasing the baseline risk of treatment-related leukemia even before transplant.

CHIP testing is not yet standard at the start of Hodgkin lymphoma therapy, but this research illustrates why the toxicity difference between ABVD and BEACOPP has real, long-term consequences for some patients.

Response-adapted therapy: the modern approach

The most significant recent development in Hodgkin lymphoma treatment is the use of interim PET scanning to guide regimen decisions — a strategy that shifts the ABVD vs BEACOPP debate considerably.

In PET-adapted strategies, patients start on ABVD and receive an interim PET scan after 2 cycles. If the scan is negative (no metabolic activity in lymph nodes), treatment continues with ABVD or is de-escalated to AVD (dropping bleomycin to reduce pulmonary toxicity). If the scan is positive, treatment escalates to BEACOPP for the remaining cycles.

The RATHL trial in the UK and the SWOG S0816 trial in the US both demonstrated that this approach is feasible: most patients with advanced-stage disease have a negative interim PET and can complete treatment with ABVD, while the minority with a positive interim PET receive escalated therapy without losing the initial window for cure. This strategy attempts to give the highest-risk patients BEACOPP's intensity while sparing lower-risk patients from its toxicity.

The brentuximab vedotin research from Eric Jacobsen's group — specifically the ECHELON-2 trial of brentuximab vedotin plus chemotherapy for CD30-positive lymphoma — showed that targeted antibody-drug conjugates can improve outcomes in CD30-expressing lymphoid malignancies with manageable toxicity [1]. In classical Hodgkin lymphoma, the ECHELON-1 trial (building on the same brentuximab platform) showed that replacing bleomycin with brentuximab in the A+AVD regimen reduced progression events compared to ABVD, with less pulmonary toxicity. This is gradually reshaping front-line choices for advanced disease.

Fertility and long-term health

For patients of reproductive age, BEACOPP's alkylating agents — cyclophosphamide and procarbazine — are among the most gonadotoxic agents in oncology. Procarbazine in particular causes irreversible testicular and ovarian failure in a significant proportion of patients. The rate of infertility after escalated BEACOPP is substantially higher than after ABVD.

ABVD does not include alkylating agents. While it can affect fertility temporarily through general illness and treatment stress, most men and women who receive ABVD have better preserved reproductive function than those who receive BEACOPP.

For young patients, this difference is often decisive. Fertility-sparing measures — sperm banking, oocyte cryopreservation, ovarian tissue preservation — should be discussed before starting any treatment, but the urgency is higher if BEACOPP is under consideration. Many oncologists will choose ABVD for young patients with early-stage or intermediate-risk disease specifically to preserve fertility, even if BEACOPP might offer a slightly higher chance of first-remission disease control.

Bleomycin lung toxicity

Both regimens contain bleomycin, which can cause pulmonary fibrosis — particularly in patients who are older, smoke, have pre-existing lung disease, or receive supplemental oxygen. Clinicians monitor pulmonary function during treatment and may drop bleomycin if lung function deteriorates.

Many centers now prefer A+AVD (substituting brentuximab vedotin for bleomycin) for patients at elevated pulmonary risk, since the ECHELON-1 data showed comparable efficacy with less lung toxicity in advanced-stage Hodgkin lymphoma.

What's changing

The field is moving toward more individualized treatment based on early PET response, molecular markers, and targeted agents. The success of brentuximab vedotin in CD30-positive lymphoid cancers — including Hodgkin lymphoma — is reshaping first-line choices [1]. Checkpoint immunotherapy (pembrolizumab, nivolumab), which works by releasing an immune brake that Hodgkin lymphoma exploits through PD-L1 overexpression, is now FDA-approved in relapsed or refractory Hodgkin lymphoma and is under study in front-line settings.

Long-term, the goal is to identify at diagnosis which patients are likely to achieve durable remission with ABVD alone, so that BEACOPP can be reserved for the minority who genuinely need its intensity. Tumor biomarkers, baseline metabolic tumor volume on PET, and molecular subtyping of the lymphoma are all being studied as predictive tools.

Questions to ask your oncologist

• What is my stage, and do I have high-risk features that would favor BEACOPP over ABVD upfront?
• Is a PET-adapted strategy an option — start with ABVD and escalate only if the interim PET is positive?
• What are the estimated cure rates with each regimen for my specific presentation?
• Am I at elevated risk for bleomycin lung toxicity, and does that change the calculus?
• Should I bank sperm or pursue fertility preservation before starting treatment?
• Is A+AVD (brentuximab vedotin-based) an option for my case, and how does it compare to ABVD or BEACOPP for my stage?

The bottom line

ABVD is the standard first-line regimen for most patients with classical Hodgkin lymphoma in the United States, offering high cure rates with substantially less long-term toxicity than escalated BEACOPP. BEACOPP produces better initial disease control in advanced-stage patients but carries higher risks of infertility and secondary leukemia. Most experts use a PET-adapted strategy — starting with ABVD and escalating to BEACOPP only for patients with a positive interim PET scan. For young patients, the fertility and secondary malignancy risks from BEACOPP weigh heavily in favor of starting with ABVD unless there is a clear high-risk reason to do otherwise.